Results 151 to 160 of about 1,098,931 (194)

Resistance to Bruton Tyrosine Kinase Inhibitors

Hematology/Oncology Clinics of North America
Targeting Bruton tyrosine kinase (BTK) has revolutionized the therapy for chronic lymphocytic leukemia. As patients remain on therapy, however, resistance develops progressively over time. The most common mechanism of resistance to covalent BTK inhibitors is mutation of the C481 target residue to serine, abrogating covalent binding.
openaire   +2 more sources

Inhibitors of brutons tyrosine kinase

2012
HONIGBERG LEE, VERNER ERIK, PAN ZHENGYING, MODY TARAK   +3 more
  +19 more sources

Inhibitors of bruton's tyrosine kinase

2015
DOMINIQUE ROMYR, KONG NORMAN, LOU YAN, LOPEZ-TAPIA FRANCISCO JAVIER, SO SUNG-SAU   +4 more
  +31 more sources

Inhibitors of Bruton's tyrosine kinase

2010
BERTHEL STEVEN, FIROOZNIA FARIBORZ, FISHLOCK DANIEL, HONG JUN-BAE, LOU YAN, LUCAS MATTHEW, OWENS TIMOTHY D, SARMA KESHAB, SWEENEY ZACHARY KEVIN, TAYGERLY JOSHUA PAUL GERGELY   +9 more
  +16 more sources

INHIBITORS OF BRUTON'S TYROSINE KINASE

2014
LOPEZ-TAPIA FRANCISCO JAVIER, SO SUNG-SAU, QIAO QI, DOMINIQUE ROMYR   +3 more
  +20 more sources

Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials

Molecules, 2023
Anna Krupa, Dariusz Pawlak, Justyna Magdalena Hermanowicz   +2 more
exaly  

Pharmacovigilance analysis of cardiac risks associated with Bruton tyrosine kinase inhibitors

Expert Opinion on Drug Safety, 2023
Yang Cao, Xiaofei Ye
exaly  

Emerging small-molecule inhibitors of the Bruton’s tyrosine kinase (BTK): Current development

European Journal of Medicinal Chemistry, 2021
Tian-tai Zhang, Dongmei Wang
exaly